The values of medicine

Multi-centre generalisability of deep learning-based dose prediction for head and neck radiotherapy using DAHANCA real-world data.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026

Evaluating the adaptation rates for esophageal cancer: Impact of the setup error contribution and of the dosimetric threshold.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2026

Scalable, memory-efficient robust proton therapy optimization through beamlet-free treatment planning.

Medical physics·2025

Dynamic proton arc treatment planning study for oesophageal cancer.

Physics and imaging in radiation oncology·2025

Towards faster plan adaptation for proton arc therapy using initial treatment plan information.

Physics and imaging in radiation oncology·2025

Anticipating potential bottlenecks in adaptive proton FLASH therapy: a ridge filter reuse strategy.

Physics in medicine and biology·2025

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

The Lancet. Oncology·2026

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

The Lancet. Oncology·2026

Advancing oncology education in low-income and middle-income African settings: global insights for local action.

The Lancet. Oncology·2026

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

The Lancet. Oncology·2026

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

The Lancet. Oncology·2026

Related Experiment Videos

The values of medicine

Related Concept Videos

Multi-centre generalisability of deep learning-based dose prediction for head and neck radiotherapy using DAHANCA real-world data.

Evaluating the adaptation rates for esophageal cancer: Impact of the setup error contribution and of the dosimetric threshold.

Scalable, memory-efficient robust proton therapy optimization through beamlet-free treatment planning.

Dynamic proton arc treatment planning study for oesophageal cancer.

Towards faster plan adaptation for proton arc therapy using initial treatment plan information.

Anticipating potential bottlenecks in adaptive proton FLASH therapy: a ridge filter reuse strategy.

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Advancing oncology education in low-income and middle-income African settings: global insights for local action.

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

Related Experiment Videos

The values of medicine

Related Concept Videos

Related Articles